Filing Flows › PAVmed (PAVM) › Q1 2025
PAVmed (PAVM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
PAVmed (PAVM) reported revenue of $8K for the first quarter 2025 (Q1 2025), -99% from a year earlier and -20% from the quarter before.
PAVmed, Q1 2025: revenue $8K (-99% year over year), net earnings $18.6M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8K | -20% | -99% |
| Operating profit | −$5.4M | — | — |
| Net earnings | $18.6M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $8K in Q1 2025, down 99% year over year and down 20% from the previous quarter.
Operating costs exceeded revenue by $5.4M, an operating margin of -68075.0%. Total costs fell 64% while revenue fell 99%. Net earnings were $19.0M ($18.6M including minority interests, which bore $345K of losses). The effective tax rate was 0.0%. Non-operating items added $24.1M, 129% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.6M. Non-cash charges added back $43K of depreciation and amortization and $930K of share-based compensation. Working capital and other items used $21.2M. Capital expenditures of $6K exceeded it, leaving free cash flow of −$1.6M.
Questions
What was PAVmed's revenue in the first quarter 2025?
PAVmed (PAVM) reported revenue of $8K for the first quarter 2025 (Q1 2025), -99% from a year earlier and -20% from the quarter before.
Source: PAVmed 10-Q on SEC EDGAR.